## **School of Medical and Allied Sciences**

Pharmacy ETE - May 2023

Time: 3 Hours Marks: 75

## Sem VIII - BP804ET - Pharmaceutical Regulatory Science

Your answer should be specific to the question asked Draw neat labeled diagrams wherever necessary

| 1.  | Define clinical studies?   | K1 CO1 | (2)  |
|-----|--|--------|------|
| 2.  | Interpret Drug discovery.  | K2 CO1 | (2)  |
| 3.  | Name the regulatory authorities of: i. India iii. EU ii. US iv. Australia.             | K1 CO2 | (2)  |
| 4.  | Illustrate the term IND and NDA.   | K2 CO2 | (2)  |
| 5.  | What is the Certificate of Pharmaceutical Product?                                     | K1 CO3 | (2)  |
| 6.  | Outline modules of CTD   | K2 CO3 | (2)  |
| 7.  | Define the term Pharmacovigilance.   | K1 CO4 | (2)  |
| 8.  | Explain the role of "Pharmacovigilance" in clinical research.                          | K2 CO4 | (2)  |
| 9.  | Define regulatory affairs  | K1 CO5 | (2)  |
| 10. | Summarize briefly "Market Authorization Application(MAA)".                             | K2 CO5 | (2)  |
| 11. | Model of "Stages of drug discovery".  OR   | K3 CO1 | (5)  |
|     | Organize a note on "Concept of generics".  |        |      |
| 12. | Contrast the procedure for the export of generic formulations.                         | K4 CO1 | (5)  |
| 13. | Choose the application and approval process for New Drug Application.                  | K3 CO2 | (5)  |
| 14. | List about Organization structure and Overview of regulatory authorities of India.  OR | K4 CO2 | (5)  |
|     | Motive of NDA and ANDA.  |        |      |
| 15. | Identify the various types of technical documentation.                                 | K3 CO3 | (5)  |
| 16. | Write down the function of ASEAN Common Technical Document. OR                         | K4 CO3 | (5)  |
|     | Examine the procedure for export of Pharmaceutical products.                           |        |      |
| 17. | Elaborate cGMP (Current Good Manufacturing Process).                                   | K6 CO5 | (5)  |
| 18. | Evaluate the "Pharmacovigilance-safety monitoring" in clinical trials.                 | K5 CO4 | (10) |
| 19. | Discuss code of federal regulation with respect to Part 2.  OR                         | K6 CO5 | (10) |
|     | Elaborate in detail about the content of "Orange Book".                                |        |      |